{"id":"W4221038606","doi":"10.1158/1538-7445.sabcs21-pd10-05","title":"Abstract PD10-05: Activity of atezolizumab (atezo) plus paclitaxel (pac) in metastatic triple-negative breast cancer (mTNBC) according to Burstein molecular subtype: Analysis of the IMpassion131 trial","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Atezolizumab; Medicine; Oncology; Internal medicine; Triple-negative breast cancer; Taxane; Clinical endpoint; Breast cancer; Population; Progression-free survival; Paclitaxel; Adjuvant; Cancer; Randomized controlled trial; Chemotherapy; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001820985,0.0003002718,0.001245369,0.001383776,0.0002466181,0.00002112536,0.0006521174,0.00007239978,0.001450083],"category_scores_gemma":[0.0004781017,0.000231004,0.0004535868,0.007427371,0.0003794555,0.0001805626,0.0005502726,0.001159876,0.000002062397],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003541966,"about_ca_system_score_gemma":0.002595639,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.03016133,"about_ca_topic_score_gemma":0.00193217,"domain_scores_codex":[0.994838,0.0008564268,0.0007048966,0.0006836469,0.002100423,0.0008166242],"domain_scores_gemma":[0.9971921,0.0005745607,0.0004287354,0.0009368005,0.0006212101,0.0002466168],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.2058678,0.001094745,0.01227781,0.0005850623,0.005090245,0.0001597734,0.005912255,0.05608771,0.6317598,0.0002008319,0.0002955707,0.08066838],"study_design_scores_gemma":[0.1031315,0.002339702,0.5722371,0.001280584,0.002421642,0.00004492801,0.01882647,0.002596959,0.2942352,0.001013292,0.0008352571,0.001037357],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.99113,0.001018985,0.000110672,0.003619049,0.0002983984,0.002452763,0.001233976,0.00001920018,0.0001169435],"genre_scores_gemma":[0.9973794,0.00009860799,0.00008409336,0.0001045179,0.00008845009,0.001842849,0.00001228455,0.00006189353,0.0003279631],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5599593,"threshold_uncertainty_score":0.9994627,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08240046586389813,"score_gpt":0.4384546055163097,"score_spread":0.3560541396524116,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}